Effects of Medium Cut-Off Versus High-Flux Hemodialysis Membranes on Biomarkers: A Systematic Review and Meta-Analysis

Maryam Kandi¹, Romina Brignardello-Petersen¹, Rachel Couban¹, Celina Wu², and Gihad Nesrallah²,³

Abstract

Background: Medium cut-off (MCO) membranes enhance large middle-molecule clearance while selectively retaining molecules >45 000 Da.

Objectives: We undertook a systematic review and meta-analysis comparing the effects of MCO versus high-flux membranes on biomarkers.

Methods: We searched MEDLINE, Embase, CINAHL, Cochrane Library, and Web of Science from January 2015 to July 2020, and gray literature sources from 2017. We included randomized (RS) and nonrandomized studies (NRS) comparing MCO and high-flux membranes in adults (>18 years) receiving maintenance hemodialysis. We performed study selection, data extraction, and quality appraisals in duplicate and used the Grading of Recommendations Assessment, Development, and Evaluation framework. Outcomes included solute removal (plasma clearance or dialysate quantitation), reduction ratios, and predialysis serum concentrations for a range of prespecified large middle molecules.

Results: We identified 26 eligible studies (10 RS and 16 NRS; N = 1883 patients; patient-years = 1366.3). The mean difference (MD) for albumin removal was 2.31 g per session (95% confidence interval [CI], 2.79 to 1.83; high certainty), with a reduction in predialysis albumin of −0.12 g/dl (95% CI, −0.16 to −0.07; I² = 0%; high certainty) in the first 24 weeks, returning to normal (MD = −0.02 g/dl, 95% CI, −0.07 to −0.03; I² = 56%; high certainty) after 24 weeks. We also found with high certainty that MCO dialysis resulted in a large increase (standardized mean difference [SMD] > 2.0 for all) in β2-microglobulin, κ- and λ-free light chains, and myoglobin removal, resulting in moderate (SMD > 0.5) to large (SMD > 0.8) reductions in predialysis concentrations for all of these solutes. Medium cut-off dialysis increased the reduction ratio for tumor necrosis factor-alpha (TNF-α) by 7.7% (95% CI, 4.7 to 10.6; moderate certainty), and reduced predialysis TNF-α by SMD −0.48 (95% CI, −0.91 to −0.04; moderate certainty). We found with moderate certainty that MCO dialysis had little to no effect on predialysis interleukin-6 (IL-6) plasma concentrations. Medium cut-off dialysis reduced mRNA expression of TNF-α and IL-6 in peripheral leukocytes by MD −15% (95% CI, −19.6 to −10.4; moderate certainty) and −8.8% (95% CI, −10.2 to −7.4; moderate certainty), respectively.

Conclusion: Medium cut-off dialysis increases the clearance of a wide range of large middle molecules and likely reduces inflammatory mediators with a concomitant transient reduction in serum albumin concentration. The net effect of MCO dialysis on large middle molecules could translate into important clinical effects.
Introduction

Uremic toxins exhibit a wide range of physiochemical properties leading to diverse molecular and cellular level effects that contribute to morbidity and mortality among patients with end-stage renal disease. Earlier membrane technologies that provided small solute (<500 Da) clearance were supplanted by high-flux membranes that were specifically engineered to enhance β2-microglobulin removal but provide minimal diffusive clearance above 15 kDa. Solutes above the molecular weight cut-off of high-flux membranes—so-called large middle molecules (15-60 kDa)—comprised a diverse group of biomarkers including cytokines, adipokines, hormones, and other proteins that are implicated in chronic inflammation, cardiovascular disease, and secondary immunodeficiency. Technologies that expand the range of dialyzable solutes within this range therefore may represent an opportunity to narrow the “clearance gap” between dialysis membranes and healthy kidneys.

A novel medium cut-off (MCO) membrane (Theranova 400/500, Baxter Healthcare, Deerfield, Illinois) removes large middle molecules while selectively excluding albumin and other large molecules above 45 kDa. This is achieved by new membrane engineering processes that produce larger pores falling within a narrow diameter distribution, leading to a “steep” sieving curve, with high selectivity at the target “cut-off” molecular weight, thereby optimizing the membrane’s depuration profile, and potentially leading to better outcomes.

We conducted a systematic review and meta-analysis on the comparative effects of MCO versus high-flux membranes in hemodialysis and have reported clinical outcomes in a separate manuscript. This report describes the effects of MCO dialysis on selected biomarkers of known prognostic importance, falling within the expanded range of molecular weights to which MCO membranes are permeable.

Methods

Protocol and Registration

We registered our protocol with PROSPERO (CRD42020204636; Appendix A, with amendments), and prepared this article in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses. Detailed methods are in Appendix B.
Eligibility Criteria
We included randomized and nonrandomized studies, from 2015, published in any language, enrolling adult outpatients receiving maintenance hemodialysis with MCO membranes and related prototypes, excluding studies of high cut-off and “super high-flux” membranes. Eligible comparators were high-flux membranes used for hemodialysis, excluding studies of convective modalities. Prespecified outcomes are in Appendix B. Selected biomarkers included albumin-related measures, representative middle molecules, and inflammatory markers. Given the breadth of analytes included in the published literature, we selected a priori a range of large middle molecules that were most frequently reported in the subset of studies identified during our pilot search that have established prognostic significance, and that spanned the entire range of applicable molecular weights.

Information Sources
We searched MEDLINE, Embase, CINAHL, the Cochrane Library, and Web of Science from January 2015 to July 2020. We included abstracts from prespecified major conferences to 2017. We cross-referenced our search results with a database provided by the manufacturer.

Search
Hemodialysis and MCO membranes were the main search concepts. We combined synonyms for each using the OR operator, then combined these concepts using AND operator. Our final search strategy is in Appendix C.

Study Selection
We used EndNote X9.3 for deduplication and DistillerSR for screening in duplicate.

Data Collection Process
Working independently, reviewers extracted data into standard forms with verification by a second reviewer.

Data Items
Details are in Appendix A. Extracted measures included solute removal, removal ratios (adjusted for the hemococoncentrating effects of ultrafiltration), and (equilibrated) predialysis serum solute concentrations.

Risk of Bias in Individual Studies
Two reviewers independently assessed risk of bias using the Cochrane “RoB” tool version 2 for randomized studies (https://www.riskofbias.info/welcome/rob-2-0-tool) and the ROBINS-I tool for nonrandomized studies (https://www.riskofbias.info/welcome/home). We did not consider an open-label design serious risk of bias for outcome measurement for the laboratory-based measures included in this report.

Summary Measures
We extracted change scores and corresponding standard errors and used $P$ values to impute the standard error for change where required, then calculated the mean difference (MD) between groups. Where change scores were not available, we used final values instead. Where units of measure differed for a given outcome, we calculated standardized mean differences (SMD) as Cohen’s $d$ where values above 0.2, 0.5, and 0.8 correspond to small, medium, and large effects, respectively.

Synthesis of Results
We pooled randomized and nonrandomized studies separately using random effects models with the generic inverse variance method for weighting the studies. We used fixed-effects models when pooling 2 studies to avoid overweighting where necessary. We assessed heterogeneity with the $I^2$ statistic.

Risk of Bias Across Studies
Where possible, we used funnel plots to assess for publication bias.

Additional Analyses
We used subgroup analyses to explore heterogeneity. Study duration was a prespecified subgroup as we anticipated that the effects of enhanced large middle-molecule clearance could be cumulative over time. The method of measurement of solute removal (blood-side vs dialysate quantitation) and baseline removal ratio were subgroups that we identified post hoc. We used the median value for follow-up duration and removal ratio as the cut-point for each subgroup analysis. We also used subgroup analysis for selected outcomes where we considered differences between short- versus long-term effects as potentially clinically important, for example, for effects on serum albumin.

Certainty of Evidence
We assessed the certainty of evidence for each outcome using the GRADE approach and summarized these assessments in a Summary of Findings Table using GRADEpro: https://gdt.gradepro.org. Evidence certainty was rated as very low, low, moderate, or high. Because we used ROBINS-I to assess risk of bias for nonrandomized studies, both randomized studies and nonrandomized studies started...
with a high certainty rating and were downgraded 1, 2, or 3 levels for risk of bias,\textsuperscript{8,9} inconsistency,\textsuperscript{10} indirectness,\textsuperscript{11} imprecision,\textsuperscript{12} or publication bias.\textsuperscript{13} We did not downgrade for inconsistency when the effect estimates from all included studies were large, that is, SMDs $\geq 0.8$, because heterogeneity of effects ranging between large and very large would not reduce our certainty in the pooled estimate. We used validated algorithms embedded in the GRADEpro platform to generate informative narrative statements describing treatment effects and their associated levels of certainty and used the generated phrasing throughout this article to guard against subjective judgments (Tables 2-4, column labeled “What Happens”).\textsuperscript{14} For estimates based on the SMD, we used descriptors for effect sizes based on standard thresholds for interpreting Cohen’s $d$, as described above.

Results

Study Selection

Figure 1 shows study selection details. We included 26 studies in this review of biomarkers,\textsuperscript{15-40} excluding 5 reports of exclusively clinical outcomes.\textsuperscript{41-45} Groupings of related citations are in Appendix D.

Study Characteristics

Among 26 unique studies included in this review, 10 were randomized trials,\textsuperscript{16-24,44} including 2 parallel arm randomized studies\textsuperscript{15,16} and 8 crossover studies that included 1883 participants followed for a total of 1366.3 person-years. Among the nonrandomized studies, 3 were cohort studies,\textsuperscript{25-27} and the remainder used before-after designs. All randomized studies were published as peer-reviewed full texts; 9 nonrandomized studies were available as abstracts,\textsuperscript{26,28-30,32-35,37} Details of patient, study design, and intervention characteristics are in Table 1. Theranova was the only MCO membrane described in eligible studies. All the included studies enrolled patients who were on maintenance hemodialysis and were without acute cardiovascular or infectious complications for at least 3 months. Study participants from diverse geographies underwent thrice-weekly hemodialysis with conventional prescriptions and anticoagulation (held constant throughout) using Theranova 400/500 or high-flux membranes.

Studies reported 3 main treatment effects for biomarkers: (1) removal (or reduction) ratio, analogous to the familiar urea reduction ratio, that is, the predialysis to postdialysis difference in a solute’s concentration divided by the predialysis value and corrected for the hemococoncentrating effects of ultrafiltration; (2) mass removal determined either through blood-side measurements (reported as plasma clearance in ml/min) or through direct dialysate quantitation (g or mg removed per hemodialysis session); and (3) predialysis (equilibrated) solute concentrations.

Risk of Bias Within Studies

Attrition was the primary form of bias within studies, as is typical with dialysis study populations.

Synthesis of Results

Effect estimates and their certainty ratings with explanatory footnotes are in Summary of Findings Tables (Tables 2-4). Where the certainty of estimates arising from randomized and nonrandomized studies differed, we present only the estimate of higher certainty. A comprehensive Summary of Findings Table is in Appendix G. Unless stated otherwise, we describe overall effects below, with details of subgroup effects in Tables 2 to 4 and in forest plots in Appendix E.

Albumin. Albumin-related measures are in Table 2. The pooled estimate from 5 randomized studies showed greater albumin removal with MD 2.31 g per session (95% confidence interval [CI], 2.79 to 1.83; high certainty) and a higher reduction ratio (3 randomized studies) 2.39% (95% CI, 3.68 to 1.11; high certainty) with MCO dialysis, with similar results in nonrandomized studies. Subgroup analyses examining short-term (<24 weeks) versus long-term follow-up (≥24 weeks) were of lower certainty; hence, we combined all available data from randomized studies and nonrandomized studies and found with high certainty that MCO dialysis reduced predialysis albumin by −0.12 g/dl (95% CI, −0.16 to −0.07; $I^2 = 0\%$) over the short term. Over long-term follow-up (24-52 weeks), MCO dialysis had a trivial to no effect on serum albumin levels with MD −0.02 g/dl (95% CI, −0.07 to −0.03; $I^2 = 56\%$; high certainty). No studies reported hypalbuminemia that required albumin infusion or discontinuation of treatment with MCO membranes.

Middle molecules. Effects on middle molecules are in Table 3.

β2-microglobulin (11.8 kDa). Pooling 4 randomized studies, we found that MCO dialysis results in a large increase in β2-microglobulin removal with SMD 1.83 (95% CI, 0.02 to 3.64; high certainty) with similar results from nonrandomized studies. The pooled reduction ratio from 7 randomized studies was higher with MCO dialysis with MD 8.0% (95% CI, 2.8 to 13.2; high certainty). Medium cut-off dialysis lowered predialysis β2-microglobulin to a moderate extent with SMD −0.41 (95% CI, −0.86 to −0.03; moderate certainty) with results from 6 randomized studies downgraded for inconsistency with high certainty of trivial to no effect over the short-term (12 weeks), and moderate certainty of a moderate effect (SMD −0.54, 95% CI, −1.0 to −0.08) over long-term (≥12 weeks) treatment. The estimate based on 6 nonrandomized studies was similar with high certainty.

Myoglobin (17 kDa). Three randomized studies found that MCO dialysis results in a large increase in myoglobin removal with SMD 2.9 (95% CI, 1.31 to 4.49; high cer-
tainty). The reduction ratio for myoglobin was 30.3% higher with MCO dialysis (95% CI, 15.5 to 45.0; high certainty) with an estimate based on 5 randomized studies. We found similar results (high certainty) with 6 nonrandomized studies. Medium cut-off dialysis reduced predialysis myoglobin moderately with SMD $-0.51$ SD (95% CI $-0.85$ to $-0.16$; moderate certainty) based on 2 randomized studies.

**Kappa free light chains (22.5 kDa).** Medium cut-off dialysis had a large effect on kappa free light chains ($\kappa$-FLC) removal with SMD 3.89 (95% CI, 3.45 to 4.33; high certainty), based on 2 randomized studies. The reduction ratio for $\kappa$-FLC was similarly increased with MD 14.9% (95% CI, 8.3 to 21.4; high certainty); results were similar in nonrandomized studies. Predialysis $\kappa$-FLC decreased by SMD $-0.39$ (95% CI, $-0.61$ to $-0.16$; high certainty) with MCO dialysis based on 5 randomized studies, with similar results from nonrandomized studies. In the subgroup with long-term treatment (≥24 weeks), MCO dialysis had a larger effect with SMD $-0.49$ (95% CI, $-0.79$ to $-0.20$; $I^2 = 24\%$).
| 1st author                  | Publication type | Country (number of centers) | Number of participants enrolled (number analyzed) | Weeks follow-up (baseline [HF] + intervention [MCO-HD]) | Mean age ± SD (years) | % Male | Interventions                                      | Reported outcomes                                                                 |
|----------------------------|-----------------|-----------------------------|---------------------------------------------------|---------------------------------------------------------|------------------------|--------|---------------------------------------------------|----------------------------------------------------------------------------------|
| **Randomized studies**     |                 |                             |                                                   |                                                         |                        |        |                                                   |                                                                                  |
| **Parallel arm studies**   |                 |                             |                                                   |                                                         |                        |        |                                                   |                                                                                  |
| Lim et al.15,44             | Full text       | Korea (1)                   | 50 (49)                                           | 12                                                      | I: 62.2 ± 13.7         | 66%    | I: Theranova 400 C: FxCordiax 80 or 60           | Survival, QoL (KDQOL), pruritus, adverse events, ERI, iron use, albumin (predialysis), MM |
| Weiner et al.16             | Full text       | USA (21)                    | 172 (130)                                         | 24                                                      | 59 ± 13                | 39%    | I: Theranova 400 C: FxCordiax 80 or 60           | Survival, hospitalization, QoL (KDQOL, EQ-5D-5L), albumin (predialysis), MM       |
| **Randomized crossover trials** |              |                             |                                                   |                                                         |                        |        |                                                   |                                                                                  |
| Belmouaz et al.17           | Full text       | France (1)                  | 40                                                | 26 (13/arm)                                            | 75.5 ± 9.9             | 70%    | I: Theranova 500 C: Elisio 21H                   | Survival, ERI, iron utilization, albumin RR, albumin (predialysis), MM            |
| Cordeiro et al.18           | Full text       | Brazil (1)                  | 16                                                | 8 (4/arm)                                              | 40.7 ± 13.5            | 69%    | I: Theranova 400 C: PS (Diacap)                  | Albumin (predialysis), MM                                                         |
| Kirsch et al. (study 1)19   | Full text       | Austria (1)                 | 19                                                | 2 (1/arm)                                              | 55.4 ± 13.4            | 63%    | I: Prototype “AA” C: FxCordiax 80VR             | Albumin loss, MM                                                                  |
| Kirsch et al. (study 2)19   | Full text       | Germany (1)                 | 20                                                | 2 (1/arm)                                              | 65.4 ± 12.2            | 80%    | I: Prototype “AA” C: FxCordiax 80VR             | Albumin loss, MM                                                                  |
| Maduell et al.21            | Full text       | Spain (1)                   | 21                                                | 2 (1/arm)                                              | 63.2 ± 16              | 82%    | I: Theranova 400 C: FxCordiax 80                 | Albumin loss, albumin RR, MM                                                     |
| Maduell et al.20            | Full text       | Spain (1)                   | 21                                                | 2 (1/arm)                                              | 65.4 ± 13              | 76%    | I: Theranova 400 C: Helixone                     | Albumin loss, albumin RR, MM                                                     |
| Santos et al.22             | Full text       | Spain (1)                   | 13                                                | 2 (1/arm)                                              | 60.1 ± 4.6             | 92%    | I: Theranova 500 C: FxCordiax 80VR              | Bleeding, extracorporeal circuit clotting, aPTT, anti-Xa, Albumin loss, MM       |
| Sevinc et al.23             | Full text       | Turkey (2)                  | 52 (42)                                           | 26 (13/arm)                                            | 56.4 (median)          | 58%    | I: Theranova 500 C: Helixone                     | Adverse events, albumin (predialysis), MM, inflammatory markers                  |
| Zickler et al.24            | Full text       | Germany (2)                 | 50 (47)                                           | 4 (+8-week extension study)                            | I: 58.1 ± 16.6         | 38%    | I: MCO-C-H00 C: Revaclear 400                   | Survival, adverse events, CRP, albumin (predialysis), MM, inflammatory markers   |
| **Nonrandomized studies**   |                 |                             |                                                   |                                                         |                        |        |                                                   |                                                                                  |
| **Cohort studies**          |                 |                             |                                                   |                                                         |                        |        |                                                   |                                                                                  |
| Cho et al.25                | Full text       | Korea (1)                   | 57 (57)                                           | 52                                                      | I: 53.7 ± 10.9         | 58%    | I: Theranova 400 C: FxCordiax 80                 | Survival, ERI, MM, cell-free hemoglobin                                           |
| Ostojic and Markovic26      | Abstract        | Serbia (1)                  | 10                                                | 52                                                      | I: 63.2 ± 7            | 60%    | I: Theranova 500 C: Polysulfone                 | MM, hemoglobin                                                                    |
| Yeter et al.27              | Full text       | Turkey (1)                  | 47 (42)                                           | 26                                                      | 52.9 ± 16              | 63%    | I: Theranova 400 C: Cordiax 800                 | Survival, ERI, iron utilization, CRP, albumin (predialysis)                      |
| **Before-after studies**    |                 |                             |                                                   |                                                         |                        |        |                                                   |                                                                                  |
| Albrizio et al.28           | Abstract        | Italy (1)                   | 8                                                 | 2 (1/arm)                                              | 78 ± 14                | 25%    | I: Theranova 400 C: HF                          | Adverse events, myoglobin                                                         |
| Baharani et al.29           | Abstract        | England (1)                 | 8                                                 | 9 (1 + 8)                                              | 71 ± 11.8              | 75%    | I: Theranova 400 C: FxCordiax 60, 80            | Adverse events, MM                                                               |

(continued)
| 1st author       | Publication type | Country (number of centers) | Number of participants enrolled (number analyzed) | Number of follow-up (baseline [HF] + intervention [MCO-HD]) | Mean age ± SD (years) | % Male | Interventions | Reported outcomes |
|------------------|------------------|-----------------------------|---------------------------------------------------|------------------------------------------------------------|-----------------------|--------|---------------|-------------------|
| Baharani et al. 29 | Abstract         | England (1)                 | 18                                                 | 9 (1 + 8)                                                   | 73 ± 16.7             | 78%    | I: Theranova 400 C: Revaclear 300 | Adverse events, MM |
| Bove et al. 30  | Abstract         | Italy (1)                   | 8                                                  | 2 (1/arm)                                                  | NR                    | NR     | I: Theranova 400 C: Cordiax FX80 | Albumin loss, MM |
| Bunch et al. 31  | Full text        | Colombia (1)                | 99 (638)                                          | 52                                                         | 60 ± 15               | 62%    | I: Theranova C: HF               | Survival, hospitalization, safety, albumin (predialysis) |
| Cantaluppi et al. 32 | Abstract        | Italy (multiple)            | 41                                                | 26                                                         | 67.6 ± 13.4           | NR     | I: Theranova C: HF               | CRP, albumin (predialysis), MM |
| Celik et al. 33  | Abstract         | Italy (1)                   | 8                                                  | 2 (1/arm)                                                  | 66 ± 13               | NR     | I: Theranova C: HF               | Albumin RR, MM inflammatory markers, CRP (RR only) |
| D’Achiardi et al. 34 | Abstract        | Colombia (multiple)         | 52 (41)                                           | 24                                                         | 61 ± 13               | 65%    | I: MCO C: HF                      | Adverse events, albumin (predialysis), MM inflammatory markers, CRP |
| Gallo 35         | Abstract         | Italy (1)                   | 15                                                | 3                                                           | 60.5 ± 12             | 80%    | I: Theranova 400 C: HF           | ERI, CRP, albumin (predialysis), MM |
| García-Prieto et al. 36 | Full text       | Spain (1)                   | 18                                                | 3 (1/arm)                                                  | 65 ± 13               | 50%    | I: Theranova 500 C: FxCordiax 80VR | Adverse events, albumin loss and RR, MM |
| Gennone et al. 37 | Abstract         | Italy (1)                   | 11 (11)                                           | 52                                                         | 70.8 ± 9              | 73%    | I: Theranova C: HF               | PCS, MCS, ERI, albumin (predialysis), MM |
| Kim et al. 38    | Full text        | Korea (1)                   | 6 (6)                                             | 3 (1/arm)                                                  | 66.1 ± 9.1            | 100%   | I: Theranova 400 C: Rexeed-21A  | Adverse events, albumin loss, albumin RR, MM |
| Krishnasamy et al. 39 | Full text       | Australia and New Zealand (9) | 89 (79)                                           | 32 (4 + 28)                                                | 66 ± 14               | 62%    | I: Theranova 400 C: Revaclear 400 | Adverse events, QoL, RLS, ERI, CRP, albumin (predialysis) |
| Crossover studies | Full text        | Italy (1)                   | 21 (20)                                           | 26 (13 + 13)                                               | 71 ± 13               | 76%    | I: Theranova 400 C: FXB, FX10, FX80, FX100, BK1.6, BG2.1 | Survival, hospitalization, infection, albumin (predialysis), inflammatory markers |

Note. MCO-HD = medium cut-off hemodialysis; KDQOL = Kidney Disease Quality of Life instrument; ERI = erythropoiesis resistance index; MM = middle-molecules (removal, reduction ratios, or predialysis serum levels); EQ-SD-SL = EuroQol 5-Dimension Questionnaire; RR = reduction ratio; PS = polysulfone; aPTT = activated partial thromboplastin time; MCO = medium cut-off; CRP = C-reactive protein; HF = high-flux (not otherwise specified); NR = not reported; PCS = physical component summary; MCS = mental component summary; PMMA = polymethylmethacrylate; RLS = restless legs syndrome.

*Single-arm MCO-HD data without comparator group for survival and hospitalization outcomes; not amenable to meta-analysis.*
Table 2. Summary of Findings—Albumin-Related Measures.

| Outcome                                           | Anticipated absolute effects (95% CI)                                                                 | Certainty  | What happens                                                                                          |
|---------------------------------------------------|----------------------------------------------------------------------------------------------------------------|------------|-------------------------------------------------------------------------------------------------------|
|                                                   |                                                                                                              |            |                                                                                                       |
| Albumin loss (g)                                  |                                                                                                              |            |                                                                                                       |
| Follow-up: 2 weeks                                | The mean albumin loss ranged from 0.2 to 0.56 g                                                              | ⧫⧫⧫⧫ High | MCO-HD increases albumin loss slightly.                                                                |
| No. of participants: 230                          | MD 2.31 g higher                                                                                              |            |                                                                                                       |
| (5 RS)                                            | (2.79 higher to 1.83 higher)                                                                                  |            |                                                                                                       |
|                                                   |                                                                                                              |            |                                                                                                       |
| Albumin reduction ratio (%)                        |                                                                                                              |            |                                                                                                       |
| Follow-up: range, 2-26 weeks                      | The mean albumin reduction ratio ranged from 7% to 11%                                                        | ⧫⧫⧫⧫ High | MCO-HD increases albumin reduction ratio slightly.                                                    |
| No. of participants: 162                          | MD 2.39% higher                                                                                              |            |                                                                                                       |
| (3 RS)                                            | (3.68 higher to 1.11 higher)                                                                                  |            |                                                                                                       |
|                                                   |                                                                                                              |            |                                                                                                       |
| Predialysis serum albumin (g/dl)                  |                                                                                                              |            |                                                                                                       |
| Follow-up: range, 2-26 weeks                      | The mean predialysis serum albumin ranged from 3.79 to 3.94 g/dl                                              | ⧫⧫⧫⧫ High | MCO-HD reduces predialysis serum albumin slightly over the short term (<24 weeks).                     |
| Subgroup with <24-week follow-up                 |                                                                                                              |            |                                                                                                       |
| Follow-up: range, 8-13 weeks                      |                                                                                                              |            |                                                                                                       |
| No. of participants: 305                          |                                                                                                              |            |                                                                                                       |
| (5 RS)                                            |                                                                                                              |            |                                                                                                       |
| Predialysis serum albumin (g/dl)                  |                                                                                                              |            |                                                                                                       |
| Follow-up: range, 24-52 weeks                     |                                                                                                              |            |                                                                                                       |
| Subgroup with ≥24-week follow-up                 |                                                                                                              |            |                                                                                                       |
| Follow-up: range, 8-13 weeks                      | The mean predialysis serum albumin was 4.1 g/dl                                                             | ⧫⧫◯ Moderate*a | MCO-HD likely results in little to no difference in predialysis serum albumin after 24 weeks of treatment. |
| No. of participants: 129                          |                                                                                                              |            |                                                                                                       |
| (1 RS)                                            |                                                                                                              |            |                                                                                                       |
| Predialysis serum albumin (g/dl)                  |                                                                                                              |            |                                                                                                       |
| Follow-up: range, 24-52 weeks                     | The mean predialysis serum albumin ranged from 3.76 to 3.94 g/dl                                              | ⧫⧫◯ Moderate*a | MCO-HD likely results in little to no difference in predialysis serum albumin after 24 weeks of treatment. |
| Subgroup analysis—RS and NRS with ≤24-week follow-up |                                                                                                             |            |                                                                                                       |
| Follow-up: range, 8-13 weeks                      |                                                                                                              |            |                                                                                                       |
| No. of participants: 325                          |                                                                                                              |            |                                                                                                       |
| (5 RS, 1 NRS)                                     |                                                                                                              |            |                                                                                                       |
| Predialysis serum albumin (g/dl)                  |                                                                                                              |            |                                                                                                       |
| Follow-up: range, 24-52 weeks                     | The mean predialysis serum albumin ranged from 3.10 to 4.05 g/dl                                              | ⧫⧫⧫⧫ High | MCO-HD reduces predialysis serum albumin slightly within the first 24 weeks of follow-up.              |
| Subgroup analysis—RS and NRS with ≥24-week follow-up |                                                                                                             |            |                                                                                                       |
| Follow-up: range, 24-52 weeks                     |                                                                                                              |            |                                                                                                       |
| No. of participants: 2139                          |                                                                                                              |            |                                                                                                       |
| (1 RS, 7 NRS)                                     |                                                                                                              |            |                                                                                                       |

Note. CI = confidence interval; MCO-HD = medium cut-off hemodialysis; MD = mean difference; NRS = nonrandomized study; RS = randomized study.

*aEstimate prone to risk of bias due to patient attrition.

Lambda free light chains (45 kDa). Removal of lambda free light chain (λ-FLC) was increased by MCO dialysis with SMD 2.16 (95% CI, 1.8 to 2.52; high certainty), based on 3 randomized studies. The pooled estimate for the λ-FLC reduction ratio was 20.9% higher with MCO dialysis (95% CI, 15.5 to 26.2; high certainty), based on 7 randomized studies with similar results in nonrandomized studies. We found that MCO dialysis reduces predialysis λ-FLC moderately with SMD −0.53 (95% CI, −0.9 to −0.17; high certainty) with similar results from nonrandomized studies.

Cytokines and inflammatory markers

Tumor necrosis factor-alpha (17 kDa). A single randomized study reported an MD in the reduction ratio for tumor necrosis factor-alpha (TNF-α) of 7.7% (95% CI, 4.7 to 10.6; moderate certainty), and 3 randomized studies measured a predialysis TNF-α decrease of SMD −0.48 (95% CI, −0.91 to −0.04; moderate certainty) with MCO dialysis. Expression of TNF-α mRNA in peripheral white blood cells decreased by MD −15% (relative quantitation) with MCO dialysis (95% CI, −19.6 to −10.4; moderate certainty) in a single randomized study that reported this outcome.
Table 3. Summary of Findings—Middle Molecules.

| Outcome                          | Anticipated absolute effects (95% CI)                                                                 | Certainty | What happens                                      |
|----------------------------------|-------------------------------------------------------------------------------------------------------|-----------|--------------------------------------------------|
| **β2M removal (mg)**             | No. of participants: 152 (4 RS)                                                                     |           | MCO-HD results in a large increase in β2M removal. |
| Follow-up: range, 2-8 weeks      | SMD 1.83 SD higher (0.02 higher to 3.64 higher)                                                     | Higha     |                                                   |
| **β2M removal (mg)**             | No. of participants: 16 (1 NRS)                                                                     |           | MCO-HD results in a large increase in β2M removal. |
| Follow-up: range, 2-26 weeks     | SMD 1.4 SD higher (0.42 higher to 2.38 higher)                                                      | Highb,c   |                                                   |
| **β2M reduction ratio (%)**      | No. of participants: 323 (7 RS)                                                                     |           | MCO-HD increases β2M reduction ratio.             |
| Follow-up: range, 2-26 weeks     | The mean β2M reduction ratio (%) ranged from 46% to 77%                                             | Highd     |                                                   |
| Predialysis β2M                  | No. of participants: 32 (1 RS)                                                                      |           |                                                   |
| Subgroup with <12-week follow-up| SMD 0.36 SD higher (0.33 lower to 1.06 higher)                                                      | Lowe      | MCO-HD may result in little to no difference in predialysis β2M over the short term (<3 months). |
| Predialysis β2M                  | No. of participants: 403 (5 RS)                                                                     |           |                                                   |
| Subgroup with ≥12-week follow-up | SMD 0.54 SD lower (1 lower to 0.08 lower)                                                           | Moderatef | MCO-HD likely reduces predialysis β2M after 3 months of treatment. |
| Predialysis β2M                  | No. of participants: 438 (6 NRS)                                                                   |           |                                                   |
| Follow-up: range, 24-52 weeks    | SMD 0.43 SD lower (0.84 lower to 0.002 lower)                                                        | high      | MCO-HD reduces predialysis β2M slightly.         |
| Myoglobin removal                | No. of participants: 120 (3 RS)                                                                     |           |                                                   |
| Follow-up: 2 weeks               | SMD 2.9 SD higher (1.31 higher to 4.49 higher)                                                      | high      | MCO-HD likely results in a large increase in myoglobin removal. |
| Myoglobin reduction ratio (%)    | No. of participants: 242 (5 RS)                                                                     |           |                                                   |
| Follow-up: range, 2-26 weeks     | The mean myoglobin reduction ratio (%) ranged from 8% to 45%                                        | Highf     | MCO-HD results in large increase in myoglobin reduction ratio. |
| Predialysis myoglobin            | No. of participants: 118 (6 NRS)                                                                   |           |                                                   |
| Follow-up: range, 2-52 weeks     | The mean myoglobin reduction ratio (%) ranged from 12% to 44%                                      | High      | MCO-HD results in large increase in myoglobin reduction ratio. |
| Predialysis myoglobin            | No. of participants: 130 (2 RS)                                                                    |           |                                                   |
| Follow-up: 26 weeks              | SMD 0.51 SD lower (0.85 lower to 0.16 lower)                                                        | Moderateh | MCO-HD likely reduces predialysis myoglobin.      |
| Predialysis myoglobin            | No. of participants: 82 (1 NRS)                                                                    |           |                                                   |
| Follow-up: 26 weeks              | SMD 0.12 SD lower (0.55 lower to 0.31 lower)                                                        | Moderateb | MCO-HD likely reduces myoglobin prehemodialysis slightly. |
| Kappa FLC removal                | No. of participants: 78 (2 RS)                                                                     |           |                                                   |
| Follow-up: 2 weeks               | SMD 3.89 SD higher (3.45 higher to 4.33 higher)                                                      | High      | MCO-HD results in large increase in kappa FLC removal. |

(continued)
**Table 3. (continued)**

| Outcome | Anticipated absolute effects (95% CI) | Certainty | What happens |
|---------|--------------------------------------|-----------|--------------|
| Kappa FLC reduction ratio (%) | The mean kappa FLC reduction ratio (%) ranged from 53% to 72% | MD 14.85% higher (8.27 higher to 21.43 higher) | ⬤⬤⬤⬤ | MCO-HD results in large increase in kappa FLC reduction ratio. |
| Follow-up: range, 2-26 weeks | | | |
| No. of participants: 249 (5 RS) | | | |
| Predialysis kappa-FLC | SMD 0.39 SD lower (0.61 lower to 0.16 lower) | ⬤⬤⬤⬤ | MCO-HD reduces predialysis kappa FLC slightly. |
| Follow-up: range, 1-26 weeks | | | |
| No. of participants: 403 (5 RS) | | | |
| Lambda FLC removal | SMD 2.16 SD higher (1.8 higher to 2.52 higher) | ⬤⬤⬤⬤ | MCO-HD results in large increase in lambda FLC removal. |
| Follow-up: 2 weeks | | | |
| No. of participants: 118 (3 RS) | | | |
| Lambda FLC removal | SMD 3.71 SD higher (2.97 higher to 4.45 higher) | ⬤⬤⬤⬤ | MCO-HD results in large increase in lambda free light chain removal. |
| Follow-up: range, 2-3 weeks | | | |
| No. of participants: 130 (2 NRS) | | | |
| Lambda FLC reduction ratio (%) | The mean lambda FLC reduction ratio (%) ranged from 13% to 41% | MD 20.85% higher (15.53 higher to 26.16 higher) | ⬤⬤⬤⬤ | MCO-HD increases lambda-FLC reduction ratio. |
| Follow-up: range, 2-26 weeks | | | |
| No. of participants: 450 (7 RS) | | | |
| Predialysis lambda-FLC | SMD 0.53 SD lower (0.9 lower to 0.17 lower) | ⬤⬤⬤⬤ | MCO-HD reduces predialysis lambda-FLC. |
| Follow-up: range, 1-26 weeks | | | |
| No. of participants: 402 (5 RS) | | | |
| Predialysis lambda-FLC | SMD 0.34 SD lower (0.54 lower to 0.14 lower) | ⬤⬤⬤⬤ | MCO-HD reduces lambda free light chain prehemodialysis slightly. |
| Follow-up: range, 24-52 weeks | | | |
| No. of participants: 398 (4 NRS) | | | |

**Note.** CI = confidence interval; MCO-HD = medium cut-off hemodialysis; [β2M] = [β2-microglobulin]; RS = randomized study; SMD = standardized mean difference; SD = standard deviation; NRS = nonrandomized study; MD = mean difference; FLC = free light chains.

*^[a]^[I]_2^2 = 97%, but fully explained by measurement method—removal was higher when measured by plasma clearance versus dialysate quantitation.
^[b]^[SM]D > 0.8 considered a large treatment effect. Rated up 1 level.
^[c]^[S]MD > 0.8 considered a large treatment effect. Rated up 1 level.
^[d]^[I]_2^2 = 99%, heterogeneity was explained by baseline removal ratio (larger effect if removal ratio was < 70%), and was further explained by study duration (effect was attenuated with long-term treatment).
^[e]^[D]owngraded 2 levels for imprecision with only very small sample size and confidence interval crossing no effect.
^[f]^[I]_2^2 > 50% and confidence intervals do not overlap.
^[g]^[I]_2^2 = 82% with opposite directions of effect.
^[h]^[I]_2^2 = 82% with opposite directions of effect.
^[i]^[I]_2^2 = 82% with opposite directions of effect.

**Interleukin-6 (24.5 kDa).** One randomized study measured the reduction ratio for interleukin-6 (IL-6) and found little to no difference with MCO dialysis with MD −0.2% (95% CI, −3.4 to 3.0; moderate certainty). The pooled estimate for predialysis IL-6 based on 4 randomized studies showed little to no difference with MCO dialysis with SMD 0.04 (95% CI, −0.17 to 0.25; moderate certainty). A single randomized study that measured peripheral leukocyte IL-6 mRNA expression found an MD of −8.8% (95% CI, −10.2 to −7.4; moderate certainty).

**C-reactive protein.** Two randomized and 5 nonrandomized studies provided moderate and high certainty, respectively, of little to no effect on C-reactive protein.

**Additional analyses.** Correlations (Pearson’s r) between treatment effects and molecular weights were (95% CI) −0.10 (−0.78 to 0.37) for removal, 0.24 (0.06 to 0.62) for reduction ratio, and −0.55 (−0.61 to −0.27) for predialysis serum concentrations for the 4 included middle molecules.
Table 4. Summary of Findings—Inflammatory Markers and Cytokines.

| Outcome | Anticipated absolute effects (95% CI) | Certainty | What happens |
|---------|---------------------------------------|-----------|--------------|
| IL-6 reduction ratio (%) | | | |
| Follow-up: 26 weeks | The mean IL-6 reduction ratio (%) was 9.5% | MD 0.2% lower (3.44 lower to 3.04 higher) | ⨁⨁⨁⨁◯ | MCO-HD likely results in little to no difference in IL-6 reduction ratio (%). |
| Predialysis IL-6 | | | |
| Follow-up: range, 12-26 weeks | The mean IL-6 expression was 100% | MD 8.8% lower (10.2 lower to 7.4 lower) | ⨁⨁⨁◯ | MCO-HD likely reduces IL-6 expression. |
| IL-6 mRNA expression | | | |
| Follow-up: 12 weeks | The mean IL-6 expression was 100% | MD 7.67% higher (4.7 higher to 10.64 higher) | ⨁◯◯◯ | MCO-HD likely increases IL-6 reduction ratio. |
| TNF-α reduction ratio (%) | | | |
| Follow-up: 26 weeks | The mean TNF-α reduction ratio (%) was 26% | MD 7.67% higher (4.7 higher to 10.64 higher) | ⨁◯◯◯ | MCO-HD likely increases TNF-α reduction ratio. |
| TNF-α predialysis | | | |
| Follow-up: range, 12-26 weeks | The mean TNF-α expression was 100% | MD 15% lower (19.6 lower to 10.4 lower) | ⨁◯◯◯ | MCO-HD likely reduces TNF-α expression. |
| C-reactive protein | | | |
| Follow-up: 12 weeks | The mean CRP expression was 100% | SMD 0.04 SD higher (0.37 lower to 0.29 higher) | ⨁◯◯◯ | MCO-HD likely results in little to no difference in C-reactive protein. |
| C-reactive protein | | | |
| Follow-up: range, 26-52 weeks | The mean CRP expression was 100% | SMD 0 SD (0.23 lower to 0.22 higher) | ⨁⨁⨁◯ | MCO-HD results in little to no difference in C-reactive protein. |

Note. CI = confidence interval; MCO-HD = medium cut-off hemodialysis; IL-6 = interleukin-6; RS = randomized study; MD = mean difference; SMD = standardized mean difference; SD = standard deviation; TNF-α = tumor necrosis factor-alpha; NRS = nonrandomized study.

*Small overall sample size; optimal information size criterion not met.

Risk of Bias Across Studies

For the outcomes with 7 or more studies (predialysis serum albumin, albumin loss), we found no evidence of publication bias based on funnel plots.

Discussion

Principal Findings

We found with high certainty that MCO dialysis removes approximately 2 g of albumin per 4-hour conventional hemodialysis session, resulting in a decreased serum albumin level of 0.12 g/dl over the short term (<24 weeks), and returning to baseline thereafter. We found with moderate to high certainty, that compared with high-flux membranes, MCO membranes increase middle-molecule clearance as measured by direct dialysate quantitation and reduction ratios, leading to reduced predialysis serum concentrations of β2-microglobulin, κ-FLC, λ-FLC, and myoglobin—solutes representing the full spectrum of large middle molecular weights. We found little to no effect on IL-6 removal or predialysis levels, while IL-6 mRNA expression was reduced by 8.8% in peripheral leukocytes. Medium cut-off dialysis increased the reduction ratio of TNF-α with a moderate
reduction in predialysis levels and reduced peripheral leukocyte mRNA expression by 15%. Collectively, these findings are consistent with the anticipated effects of the MCO membrane, and may account for improved clinical outcomes including reduced symptom burden, recovery time, infection, hospital length of stay, and quality of life described in our separate report of clinical outcomes.3

Strengths and Limitations of this Review
To our knowledge, this is the first systematic review and meta-analysis comparing MCO with high-flux membranes. Strengths of this review include adherence to a rigorous registered protocol, a sensitive search strategy, performing study procedures in duplicate, and the use of GRADE methods.

The lack of validation of the included biomarkers as surrogate outcomes is a major limitation in this review. Although associated with important physiological processes and clinical outcomes, none of the included biomarkers meet regulatory or statistical criteria for surrogacy.46,47 A valid surrogate must not only exhibit a high degree of correlation with a “true” or clinical outcome but also reliably predict the true treatment effect in trials that included both outcomes. Therefore, despite their familiarity and frequent use in dialysis trials and guidelines, we caution against the sole use of biomarkers in clinical or other decision-making. Further limitations of this review include the exclusion of small solutes and lack of direct comparisons with convective therapies.

Comparisons With Previous Research
Albumin is a biomarker with a strong association with dialysis outcomes. Although albumin is affected by the same upstream inflammatory processes that contribute to malnutrition and accelerated cardiovascular disease, it is not in the causal pathway for death or cardiovascular events.48 Nevertheless, albumin removal has been considered a safety outcome in evaluating the effects of MCO dialysis, and the albumin loss associated with high cut-off membranes (up to 11 g/hemodialysis) has been cause for concern, prompting fresh frozen plasma or albumin infusion.49 Similar complications have arisen from high-volume postdilution hemodiafiltration (HDF).50 Our most certain estimate found that MCO dialysis removed 2.31 g of albumin per hemodialysis, with a transient decrease in predialysis albumin of 0.12 g/dl (95% CI, −0.16 to −0.07) within 24 weeks of treatment, returning to baseline thereafter. In all the included studies, albumin levels remained within the reference range, and there were no reports of albumin depletion leading to discontinuation of MCO dialysis or the need for albumin infusion. Albumin removal of 5 to 15 g/day with peritoneal dialysis51,52 and 3 to 5 g/day with HDF has not to date been identified as harmful, possibly because the theoretical harms of albumin removal by dialysis are offset by the amelioration of the uremic milieu. The inverse relationship between albumin synthesis and cytokine expression would support this logic.53 The reduced IL-6 and TNF-α expression afforded by MCO dialysis could account for the apparent compensatory response that restores serum albumin to baseline values over the longer term. A similar phenomenon was observed in a post hoc analysis of the CONTRAST study, which found similar long-term albumin levels in patients treated with HDF versus low-flux hemodialysis, despite markedly higher albumin removal with HDF.54 The effect of HDF on albumin levels was associated with relatively lower IL-6 concentrations in the CONTRAST study as well.

Serum concentrations of middle molecules and inflammatory mediators are typically several-fold higher in end-stage renal disease compared with healthy individuals. While TNF-α is 4- to 5-fold higher, κ-FLC can be anywhere from 2- to 16-fold higher in uremia.55 We found that MCO dialysis provided greater removal of β2-microglobulin, myoglobin, λ-, and κ-FLC, that translated into lower predialysis concentrations in all these solutes, especially over the longer term. Although these treatment effects were moderate to large (based on SMD values of >0.5 and >0.8, respectively), they did not result in normalization of predialysis solute concentrations.55 Nevertheless, these selected middle molecules are associated with important pathophysiological processes, including left ventricular hypertrophy (TNF-α), coronary artery disease (IL-6), impaired immunity and increased infection risk (FLCs), malnutrition and cachexia (IL-6), and several others, and reducing the overall burden of these and other uremic wastes could potentially translate into clinically meaningful effects.

Although we did not include other biomarkers in this review, we would expect similar effects on other large middle molecules. The included studies indeed reported enhanced removal of fibroblast growth factor-23,17 prolactin,19,21 α1-microglobulin19,21 complement factor D,10 and YKL-4010 with MCO dialysis. We also identified studies reporting other effects with MCO dialysis, including reduced advanced glycosylation end-product accumulation in human skin,56 increased vancomycin clearance,57 reduced in vitro vascular smooth muscle cell necrosis,58 as well as improved endothelial function and increased expression of antioxidants.59 Hence, whether mediated through direct effects on toxic solute levels, or through indirect effects such as down-regulating cytokine expression, the net effects of the MCO dialysis dialyzer could translate into meaningful clinical effects. In our corresponding report of clinical outcomes, we found with moderate to high certainty that patients treated with MCO dialysis had lower rates of infection, higher quality of life scores, less fatigue, lower symptom burden, and reduced erythropoietin resistance and iron use, all of which are consistent with the enhanced large middle-molecule clearance described here.3

We found no correlation between molecular weight and removal or reduction ratios, suggesting that MCO dialysis
had comparable effects on all selected middle molecules ranging from 11.8 to 45 kDa. The finding of comparable effects on molecules of widely variable size is not fully explained by the MCO membrane’s steep sieving curve which has a molecule weight retention onset value (the point at which the sieving coefficient drops below 0.9) at around 12 kDa, that is, that of β2-microglobulin. Above that threshold, we would expect relatively lower diffusive clearances with increasing molecular weight. In vitro and modeling studies have estimated that owing to its large pore sizes and narrow fiber diameter, the MCO membrane provides approximately 7-8000 ml of convective clearance through internal filtration, which likely accounts for most of the augmented large middle-molecule clearance, compared with high-flux membranes, and explains the uniformity of effect across the large middle-molecule spectrum. Interestingly, we found a moderately large inverse correlation between molecular weight and the effect on predialysis solute concentrations. This apparent dissociation between removal and serum solute concentrations suggests that MCO dialysis could exert indirect effects as suggested by the downregulation of IL-6 and TNF-α expression in peripheral leukocytes, and by the compensatory increase in albumin synthesis that occurs over the long term.

**Certainty of the Evidence**

Certainty was generally moderate to high across measures. Given the relatively objective measurement of biomarkers, the only major source of risk of bias was patient attrition. Patients with attrition events may have had poorer health and might have systematically different results compared with those who did not. We also found statistical heterogeneity in several estimates, primarily because they varied from large to very large treatment effects, and this did not warrant downgrading. Heterogeneity was explained by subgroup analyses. Studies with low baseline (control group) reduction ratios had larger effect sizes. Predialysis middle-molecule concentrations were generally unaffected over the short term, but significantly reduced over the longer term. Removal was higher when measured as blood-side clearance versus dialysate quantitation. Interestingly, the dissociation between these measures suggests that some plasma clearance could be due to membrane adsorption to the MCO membrane. Other sources of heterogeneity might have included differences in dialysis treatment parameters, membrane surface area, and patients’ residual renal function. Although many of the studies were relatively small, most used crossover or before-after designs, which reduced variance due to case-mix (patients served as their own controls), enabling paired analysis design and improving power and precision. In crossover studies, reduced solute concentrations following treatment with MCO dialysis could have carried over into the high-flux period; however, this carryover effect would have biased all results toward the null, and therefore did not warrant downgrading. Finally, we did not downgrade any outcomes for indirectness as would be required if they were to be used as surrogates for clinical outcomes in a guideline.

**Implications for Decision Makers**

This report is intended to provide complementary and contextual information for interpreting clinical effects of MCO dialysis and is not intended to directly inform decision-making. However, albumin has been considered a safety outcome by some authorities (eg, US Food and Drug Administration). While we found a statistically significant short-term effect on albumin removal with MCO dialysis, albumin loss with MCO dialysis appears to be transient and comparable in magnitude with other dialysis modalities.

**Conclusions**

Compared with high-flux membranes, MCO dialyzers increase the elimination of large middle molecules, resulting in decreased predialysis solute concentrations of solutes ranging between 11.8 and 45 kDa. Although MCO dialysis did not normalize serum concentrations of these solutes, the net effect of enhanced clearance within the large middle-molecule spectrum could explain the range of beneficial clinical effects reported to date. Further study will help to establish causal relationships between key biomarkers and clinical outcomes. Future studies evaluating the comparative effects of MCO hemodialysis and convective therapies are sure to generate interest as well.

**Ethics Approval and Consent to Participate**

Not applicable.

**Consent for Publication**

Not applicable.

**Availability of Data and Materials**

Not applicable.

**Declaration of Conflicting Interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was funded through an unrestricted educational grant provided by Baxter Healthcare.

**ORCID iD**

Gihad Nesrallah https://orcid.org/0000-0002-2280-3811

**Supplemental Material**

Supplemental material for this article is available online.
References

1. Wolley M, Jardine M, Hutchison CA. Exploring the clinical relevance of providing increased removal of large middle molecules. *Clin J Am Soc Nephrol*. 2018;13(5):805-814. doi:10.2215/CJN.01109117.

2. Ronco C, La Manna G. Expanded hemodialysis: a new therapy for a new class of membranes. *Contrib Nephrol*. 2017;190:124-133. doi:10.1159/000468959.

3. Kandi M, Brignardello-Petersen R, Couban R, et al. Clinical Outcomes with the Theranova Dialyzer: A Systematic Review and Meta-Analysis. *Can J Kidney Health Dis*. 2021; 8.

4. Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ*. 2019;366:j4898.

5. Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. *BMJ*. 2016; 14919. doi: 10.1136/bmj.i4919.

6. Cohen J. *Statistical Power Analysis for the Behavioral Sciences*. Hillsdale, NJ: Lawrence Erlbaum; 1988.

7. Guyatt GH, Thorlund K, Oxman AD, et al. GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles-continuous outcomes. *J Clin Epidemiol*. 2013;66:173-183. doi:10.1016/j.jclinepi.2012.08.001.

8. Guyatt GH, Oxman AD, Vist G, et al. GRADE guidelines: 4. Rating the quality of evidence–study limitations (risk of bias). *J Clin Epidemiol*. 2011;64:407-415. doi:10.1016/j.jclinepi.2010.07.017.

9. Schunemann HJ, Cuello C, Akl EA, et al. GRADE guidelines: 18. How ROBINS-I and other tools to assess risk of bias in nonrandomized studies should be used to rate the certainty of a body of evidence. *J Clin Epidemiol*. 2019;111:105-114. doi:10.1016/j.jclinepi.2018.01.012.

10. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 7. Rating the quality of evidence–inconsistency. *J Clin Epidemiol*. 2011;64:1294-1302. doi:10.1016/j.jclinepi.2011.03.017.

11. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 8. Rating the quality of evidence–indirectness. *J Clin Epidemiol*. 2011;64:1303-1310. doi:10.1016/j.jclinepi.2011.04.014.

12. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines 6. Rating the quality of evidence–imprecision. *J Clin Epidemiol*. 2011;64:1283-1293. doi:10.1016/j.jclinepi.2011.01.012.

13. Guyatt GH, Oxman AD, Montori V, et al. GRADE guidelines: 5. Rating the quality of evidence–publication bias. *J Clin Epidemiol*. 2011;64:1277-1282. doi:10.1016/j.jclinepi.2011.01.011.

14. Santesso N, Glenton C, Dahm P, et al. GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions. *J Clin Epidemiol*. 2020;119:126-135. doi:10.1016/j.jclinepi.2019.10.014.

15. Lim J-H, Jeon Y, Youk J-M, et al. Medium cut-off dialyzer improves erythropoiesis stimulating agent resistance in a hepcidin-independent manner in maintenance hemodialysis patients: results from a randomized controlled trial. *Sci Rep*. 2020;10. doi:10.1038/s41598-020-73124-x.

16. Weiner DE, Falzon L, Skoufos L, et al. Efficacy and Safety of expanded hemodialysis with the Theranova 400 dialyzer. *Clin J Am Soc Nephrol*. 2020;15:1310-1319. doi:10.2215/CJN.01210120.

17. Belmoaz M, Bauwens M, Hauet T, et al. Comparison of the removal of uraemic toxins with medium cut-off and high-flux dialysers: a randomized clinical trial. *Nephrol Dial Transplant*. 2020;35:328-335. doi:10.1093/ndt/gfz189.

18. Cordeiro ISF, Cordeiro L, Wagner CS, et al. High-flux versus high-retention-onset membranes: in vivo small and middle molecules kinetics in convective dialysis modalities. *Blood Purif*. 2020;49(1-2):8-15. doi:10.1159/000502082.

19. Kirsch AH, Lyko R, Nilsson LG, et al. Performance of hemodialysis with novel medium cut-off dialyzers. *Nephrol Dial Transplant*. 2017;32:165-172. doi:10.1093/ndt/gfw310.

20. Maduell F, Broseta JJ, Rodas L, et al. Comparison of solute removal properties between high-efficient dialysis modalities in low blood flow rate. *Ther Apher Dial*. 2020;24(4):387-392. doi:10.1111/1744-9987.13440.

21. Maduell F, Rodas L, Broseta JJ, et al. High-permeability alternatives to current dialyzers performing both high-flux hemodialysis and postfiltration online hemodiafiltration. *Artif Organs*. 2019;43(10):1014-1021. doi:10.1111/aor.13480.

22. Santos A, Macias N, Vega A, et al. Efficacy of enoxaparin in preventing coagulation during high-flux haemodialysis, expanded haemodialysis and haemodiafiltration. *Clin Kidney J*. 2021;14(4):1120-1125. doi:10.1093/ckj/sfao57.

23. Sevinc M, Hashal NB, Yilmaz V, et al. Comparison of circulating levels of uremic toxins in hemodialysis patients treated with medium cut-off membranes and high-flux membranes: Theranova in Sisli Hamidiye Etfal (THE SHE) randomized control study. *Blood Purif*. 2020;49(6):733-742. doi:10.1159/000508061.

24. Zickler D, Schindler R, Willy K, et al. Medium Cut-Off (MCO) membranes reduce inflammation in chronic dialysis patients-a randomized controlled clinical trial. *PLoS ONE*. 2017;12:e0169024. doi:10.1371/journal.pone.0169024.

25. Cho NJ, Park S, Islam MI, et al. Long-term effect of medium cut-off dialyzer on middle uremic toxins and cell-free hemoglobin. *PLoS ONE*. 2019;14:e0220448. doi:10.1371/journal.pone.0220448.

26. Ostojic A, Markovic R. P1105CAN BETTER EFFICACY OF MIDDLE WEIGHT MOLECULES REMOVAL IN DIALYSIS PATIENTS TREATED WITH MEDIUM CUT-OFF MEMBRANES PREDICT SUPERIORITY OVER CONVENTIONAL HIGH FLUX DIALYSERS? *Nephrology Dialysis Transplantation*. 2020;35. doi:10.1093/ndt/gfaa142.P1105.

27. Yeter HH, Korucu B, Akcay OF, Derici K, Derici U, Arinsoy T. Effects of medium cut-off dialysis membranes on inflammation and oxidative stress in patients on maintenance hemodialysis. *Int Urol Nephrol*. 2020;52(9):1779-1789. doi:10.1007/s11255-020-02562-3.

28. Albrizio P, Costa S, Foschi A, et al. FP466NEW MEDIUM CUTOFF MEMBRANE VS ONLINE HEMODIALIFRATATION IN CLEARANCE OF MIDDLE MOLECULES. Preliminary Results From Our Centre. *Nephrol Dial Transplant*. 2018;33(suppl 1):i193. doi:10.1093/ndt/gfy104.FP466.

29. Baharani J, Barrios B, Hopkins D, et al. UK clinical experiences of a new expanded haemodialysis therapy with a novel medium cut-off dialyzer [poster SA-PO760] Heartlands Hospital n=8, Morristone Hospital n=18. *J Amer Soc Nephrol*. 2017;28:875.

30. Bove S, D’Avanzo L, Terlizzi V, Spitti C, Scolari F. FP458COMPARISON OF HIGH FLUX HEMODIALYZERS WITH MEDIUM CUT-OFF DIALYZER ON THE REMOVAL OF MIDDLE HIGH SIZE UREMIC TOXINS.
Nephrol Dial Transplant. 2018;33(suppl 1):i190. doi:10.1093/ndt/gfy104.FP458.

31. Bunch A, Sanchez R, Nilsson LG, et al. Medium cut-off dialyzers in a large population of hemodialysis patients in Colombia: COREXH registry. Ther Apher Dial. 2021;25(1):33-43. doi:10.1111/1744-9987.13506.

32. Cantaluppi V, D’Onati G, Lacquaniti A, et al. Removal of large-middle molecules on expanded hemodialysis (HDx): a multicentric observational study of 6 month follow-up [Poster TH-PO357]. J Am Soc Nephrol. 2018;29:206.

33. Celik L, Irlando A, Mortellaro RF, Castestetto E. FP444 PLASMA MOLECULAR CHANGES IN HEMODIALYSIS PATIENTS WITH POLYARYLETHERSULFONE-POLYVINYLPPROLIDONE MEMBRANE DIALYZER (THERANOVA 400 BAXTER). Nephrol Dial Transplant. 2018;33(suppl 1):i184-1185. doi:10.1093/ndt/gfy104.FP444.

34. D’Achiardi R, Zuhiga E, Molano A, et al. P1063 PERFORMANCE OF MEDIUM CUT-OFF DIALYZERS IN EXPANDED HEMODIALYSIS PATIENTS IN COLOMBIA. Nephrol Dial Transplant. 2020;35. doi:10.1093/ndt/gfaa142.P1063.

35. Gallo M. FP539 The real-life study on expanded hemodialysis (HDx): 9 months experience of a single hemodialysis unit. Nephrol Dial Transplant. 2019;34(suppl 1):a226. doi:10.1093/ndt/gfz106.FP539.

36. Garcia-Prieto A, Vega A, Linares T, et al. Evaluation of the efficacy of a medium cut-off dialyser and comparison with other high-flux dialysers in conventional haemodialysis and online haemodiafiltration. Clin Kidney J. 2018;11(5):742-746. doi:10.1093/ckj/sfy004.

37. Gemone G, Partipilo F, Detomasso F, et al. P1084 LONG TERM EVALUATION OF THE EXPANDED HEMODIALYSIS (HDx) ON DIALYSIS ADEQUACY, ANEMIA AND QUALITY OF LIFE. Nephrol Dial Transplant. 2020;35. doi:10.1093/ndt/gfaa142.P1084.

38. Kim TH, Kim SH, Kim TY, et al. Removal of large middle molecules via haemodialysis with medium cut-off membranes at lower blood flow rates: an observational prospective study. BMC Nephrol. 2019;21:2. doi:10.1186/s12882-019-1669-3.

39. Krishnasamy R, Hawley CM, Jardine MJ, et al. A trial evaluating mid-cut-off value membrane clearance of albumin and light chains in hemodialysis patients: a safety device study. Blood Purif. 2020;49(4):468-478. doi:10.1159/000505567.

40. Cozzolino M, Magagnoli L, Ciceri P, et al. Effects of a medium cut-off (Theranova®) dialyser on haemodialysis patients: a prospective, cross-over study. Clin Kidney J. 2021;14:382-389. doi:10.1093/ckj/sfz155.

41. Alarcon JC, Bunch A, Ardila F, et al. Impact of medium cut-off dialyzers on patient-reported outcomes: COREXH registry. Blood Purif. 2021;50(1):110-118. doi:10.1159/000508803.

42. Ariza JG, Walton SM, Suarez AM, Sanabria M, Vesga JI. An initial evaluation of expanded dialysis on hospitalizations, drug utilization, costs, and patient utility in Colombia. Ther Apher Dial. 2021;25(5):621-627. doi:10.1111/1744-9987.13620.

43. Bolton S, Gair R, Nilsson L-G, et al. Clinical assessment of dialysis recovery time and symptom burden: impact of switching hemodialysis therapy mode. Patient Relat Outcome Meas. 2021;12:315-321. doi:10.2147/prom.s325016.

44. Lim JH, Park Y, Yook JM, et al. Randomized controlled trial of medium cut-off versus high-flux dialyzers on quality of life outcomes in maintenance hemodialysis patients. Sci. 2020;10:7780. doi:10.1038/s41598-020-64622-z.

45. Penny J, Salerno FR, Hur L, McIntyre C. P1062 EXPANDED DIALYSIS (HDx): IS THERE AN IMPACT ON PATIENT REPORTED SYMPTOM? Nephrol Dial Transplant. 2020;35. doi:10.1093/ndt/gfaa142.P1062.

46. Katz R. Biomarkers and surrogate markers: an FDA perspective. NeuroRx. 2004;1:189-195. doi:10.1016/j.neurx.12.189.

47. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med. 1989;8:431-440. doi:10.1002/sim.4780040407.

48. Van Gelder MK, Abrahms AC, Joles JA, et al. Albumin handling in different hemodialysis modalities. Nephrol Dial Transplant. 2018;33:906-913. doi:10.1093/ndt/gfx191.

49. Villa G, Zaragoza JJ, Sharma A, Neri M, De Gaudio AR, Ronco C. Cytokine removal with high cut-off membrane: review of literature. Blood Purif. 2014;38(3-4):167-173. doi:10.1159/000369155.

50. Cuvelier C, Tintillier M, Migali G, Van Ende C, Pochet JM. Albumin losses during hemodiafiltration: all dialyzers are not created equal—a case report. BMC Nephrol. 2019;20. doi:10.1186/s12882-019-1567-8.

51. Dulaney JT, Hatch FE Jr. Peritoneal dialysis and loss of proteins: a review. Kidney Int. 1984;26(3):253-262. doi:10.1038/ki.1984.167.

52. Balafa O, Halbesma N, Struijik DG, et al. Peritoneal albumin and protein losses do not predict outcome in peritoneal dialysis patients. Clin J Am Soc Nephrol. 2011;6:561-566. doi:10.2215/ cjn.05540610.

53. Koj A. Initiation of acute phase response and synthesis of cytokines. Biochim Biophys Acta. 1996;1317:84-94. doi:10.1016/s0925-4439(96)00048-8.

54. Den Hoedt CH, Bots ML, Grooteman MPC, et al. Online hemodiafiltration reduces systemic inflammation compared to low-flux hemodialysis. Kidney International. 2014;86:423-432. doi:10.1038/ki.2014.9.

55. Duranton F, Cohen G, De Smet R, et al. Normal and pathologic concentrations of uremic toxins. J Am Soc Nephrol. 2012;23(7):1258-1270. doi:10.1681/ASN.2011121175.

56. Viramontes Horner D, Kolhe N, Leung J, Fluck R, Selby NM, Taal MW. P1078 IMPACT OF A MEDIUM CUT-OFF DIALYZER ON SKIN AUTOFLUORESCENCE IN HEMODIALYSIS PATIENTS. Nephrol Dial Transplant. 2020;35. doi:10.1093/ndt/gfaa142.P1078.

57. Allawati H, Dallas L, Nair S, Palmer J, Thaikandy S, Hutchison C. A pharmacokinetic study comparing the clearance of vancomycin during haemodialysis using medium cut-off membrane (Theranova) and high-flux membranes (revaclear). Toxins (Basel). 2020;12:12. doi:10.3390/toxins12050317.

58. Ciceri P, Tettamanti G, Galassi A, et al. Pro-calcifying analysis of uraemic serum from patients treated with medium cut-off membrane in a prospective, cross-over study. Clin Kidney J. 2020;7:1798-1807. doi:10.1093/ckj/sfaa216.

59. Ronco C. Cytokine removal with high cut-off membrane: review of literature. Blood Purif. 2014;38(3-4):167-173. doi:10.1159/000369155.

60. Lorenzin A, Neri M, Clark WR, et al. Modeling of interdialytic filtration in Theranova hemodialyzers. Contrib Nephrol. 2012;15. doi:10.1002/sim.4780040407.